Browning of perivascular adipose tissue protects against thoracic aortic aneurysm
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm
批准号:
10580855
负责人:
YUQING Eugene CHEN
金额:
$58.62万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-04-01 至 2026-03-31
关键词:
AccelerationAddressAdipocytesAdipose tissueAffectAneurysmAortaAortic AneurysmApoptosisAtherosclerosisBlood VesselsBrown FatCardiacCardiovascular DiseasesCharacteristicsChestClinicalClinical TreatmentClinical TrialsCoculture TechniquesConditioned Culture MediaDataDevelopmentDiseaseDissectionFatty AcidsFatty acid glycerol estersFunctional disorderGenerationsGenesGenetic Predisposition to DiseaseHealthHeritabilityHomeostasisHumanHypertensionIn VitroInduction of ApoptosisInflammationInflammatoryInfusion proceduresKnockout MiceKnowledgeLesionLifeMediatingMetabolic DiseasesModelingMorbidity - disease rateMusNitrogen DioxideOperative Surgical ProceduresOther GeneticsOutcomeOxidative StressPathologyPatientsPharmaceutical PreparationsPharmacotherapyPhase II Clinical TrialsProcessPropertyProteinsRepressionResearchRisk AdjustmentRoleRuptureSignal TransductionSmooth Muscle MyocytesTestingThoracic Aortic AneurysmTransgenic MiceVascular DiseasesVascular Smooth MuscleWorkadipokinesclinical translationepidemiology studygain of functiongenetic approachin vivoinflammatory markerknock-downloss of functionmortalitynitrated conjugated linoleic acidnovelnovel drug classnovel therapeutic interventionoverexpressionparacrineperioperative mortalitypharmacologicpreventprogramsrepairedresistin
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Thoracic aortic aneurysm (TAA) is a life-threatening disease and has a high mortality rate if rupture occurs.
Currently, apart from endovascular or open surgery repair, no drug has been demonstrated to be effective for
TAA treatment. Even though some patients with TAA have evidence of a heritable aortopathy, about 75% of
TAA patients have severe aortic damage without a clear genetic etiology. The scant mechanistic knowledge is
limiting the development of medications for the treatment of TAA, thus highlighting a pressing need for better
understanding TAA formation and progression. Aorta is naturally surrounded by perivascular adipose tissue
(PVAT). Recent large-scale epidemiological studies demonstrated that PVAT was highly associated with a
significantly higher adjusted risk of all-cause cardiac mortality. We and others documented that brown-like
PVAT contributes to vascular homeostasis in health, while whitening of PVAT is dysfunctional and contributes
to development of the vascular diseases. A causal relationship between PVAT and TAA and the underlying
mechanisms remain unknown. Our preliminary studies indicate that the PVAT near the TAA lesion in patients
lost brown characteristics, and that TAA formation was dramatically increased in mice that lack normal PVAT,
suggesting that dysfunctional PVAT is associated with TAA. The conditioned medium from PVAT of TAA
patients induced apoptosis and inflammation in human aortic smooth muscle cells, suggesting that signaling
from PVAT can cause loss of vascular smooth muscle cells (VSMC) in the aorta, which may promote TAA
lesion. It is unknown whether browning of PVAT could protect against TAA. PR-domain containing 16
(PRDM16) is a determinant of browning gene programs. We show that PRDM16 expression in PVAT of TAA
patients is significantly reduced when compared to that in normal PVAT. PRDM16 inhibited resistin expression
in PVAT. We found that nitrated conjugated linoleic acid (NO2-CLA) induced the browning of human PVAT
adipocytes by mediating PRDM16 signaling. Based on these data, we hypothesize that PRDM16-mediated
PVAT browning prevents TAA formation. We will determine that 1) PRDM16 in PVAT prevents and reverses
TAA in mice; 2) PRDM16 inhibits TAA by regulating PVAT crosstalk with VSMC; 3) NO2-CLA prevents TAA by
targeting PRDM16. Outcomes will demonstrate that a previously unrecognized process involving loss of
browning features in PVAT promotes TAA formation through crosstalk to VSMC. This work will accelerate
clinical translation of a nitro-fatty acid-based treatment for TAA targeting PVAT homeostasis with this new
class of drugs, currently on clinical trials for other diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nitro-Fatty Acids and Cardiovascular Disease
-
批准号:10670429
-
项目类别:
-
资助金额:$72.04万
-
财政年份:2022
-
负责人:YUQING Eugene CHEN
-
依托单位:
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm
-
批准号:10462357
-
项目类别:
-
资助金额:$58.62万
-
财政年份:2022
-
负责人:YUQING Eugene CHEN
-
依托单位:
Development of gene editing based therapy for cardiovascular diseases
-
批准号:10652321
-
项目类别:
-
资助金额:$70.33万
-
财政年份:2021
-
负责人:YUQING Eugene CHEN
-
依托单位:
Development of gene editing based therapy for cardiovascular diseases
-
批准号:10313701
-
项目类别:
-
资助金额:$71.73万
-
财政年份:2021
-
负责人:YUQING Eugene CHEN
-
依托单位:
Development of gene editing based therapy for cardiovascular diseases
-
批准号:10441548
-
项目类别:
-
资助金额:$70.33万
-
财政年份:2021
-
负责人:YUQING Eugene CHEN
-
依托单位:
IDOL and dyslipidemia in cardiovascular diseases
-
批准号:10221773
-
项目类别:
-
资助金额:$77.39万
-
财政年份:2019
-
负责人:YUQING Eugene CHEN
-
依托单位:
IDOL and dyslipidemia in cardiovascular diseases
-
批准号:10451711
-
项目类别:
-
资助金额:$77.39万
-
财政年份:2019
-
负责人:YUQING Eugene CHEN
-
依托单位:
KLF14 and Cardiovascular Disease
-
批准号:10319617
-
项目类别:
-
资助金额:$61.86万
-
财政年份:2017
-
负责人:YUQING Eugene CHEN
-
依托单位:
KLF14 and Atherosclerosis
-
批准号:9333689
-
项目类别:
-
资助金额:$70.24万
-
财政年份:2017
-
负责人:YUQING Eugene CHEN
-
依托单位:
KLF14 and Cardiovascular Disease
-
批准号:10569551
-
项目类别:
-
资助金额:$61.86万
-
财政年份:2017
-
负责人:YUQING Eugene CHEN
-
依托单位:
MPO, HDL Dysfunction and Cardiovascular Disease
-
批准号:9265931
-
项目类别:
-
资助金额:$71.68万
-
财政年份:2015
-
负责人:YUQING Eugene CHEN
-
依托单位:
MPO, HDL Dysfunction and Cardiovascular Disease
-
批准号:9097767
-
项目类别:
-
资助金额:$71.68万
-
财政年份:2015
-
负责人:YUQING Eugene CHEN
-
依托单位:
MPO, HDL Dysfunction and Cardiovascular Disease
-
批准号:8987161
-
项目类别:
-
资助金额:$71.68万
-
财政年份:2015
-
负责人:YUQING Eugene CHEN
-
依托单位:
Regenerating Blood Vessels Using iPS Cells
-
批准号:8455086
-
项目类别:
-
资助金额:$54.4万
-
财政年份:2013
-
负责人:YUQING Eugene CHEN
-
依托单位:
Regenerating Blood Vessels Using iPS Cells
-
批准号:8603284
-
项目类别:
-
资助金额:$52.39万
-
财政年份:2013
-
负责人:YUQING Eugene CHEN
-
依托单位:
CETP and HDL Function in Cardiovascular Diseases
-
批准号:8602046
-
项目类别:
-
资助金额:$59.03万
-
财政年份:2013
-
负责人:YUQING Eugene CHEN
-
依托单位:
CETP and HDL Function in Cardiovascular Diseases
-
批准号:9086414
-
项目类别:
-
资助金额:$62.0万
-
财政年份:2013
-
负责人:YUQING Eugene CHEN
-
依托单位:
Regenerating Blood Vessels Using iPS Cells
-
批准号:8787149
-
项目类别:
-
资助金额:$51.71万
-
财政年份:2013
-
负责人:YUQING Eugene CHEN
-
依托单位:
CETP and HDL Function in Cardiovascular Diseases
-
批准号:8706225
-
项目类别:
-
资助金额:$60.76万
-
财政年份:2013
-
负责人:YUQING Eugene CHEN
-
依托单位:
CETP and HDL Function in Cardiovascular Diseases
-
批准号:8856653
-
项目类别:
-
资助金额:$61.07万
-
财政年份:2013
-
负责人:YUQING Eugene CHEN
-
依托单位:
海外基金